Virax Biolabs Group (VRAX) Stock Price, News & Analysis

Company Overview

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $0.73 to $0.80
• 50-Day Range: $0.75 to $1.11
• 52-Week Range: $0.72 to $9.00
• Volume: 45,778 shs
• Average Volume: 189,286 shs
• Market Capitalization: $3.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

Virax Biolabs Group Stock Analysis - MarketRank™

Virax Biolabs Group scored higher than 69% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Virax Biolabs Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Virax Biolabs Group has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Virax Biolabs Group has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.38% of the float of Virax Biolabs Group has been sold short.

Short Interest Ratio / Days to Cover

Virax Biolabs Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Virax Biolabs Group has recently decreased by 35.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Virax Biolabs Group does not currently pay a dividend.

Dividend Growth

Virax Biolabs Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.38% of the float of Virax Biolabs Group has been sold short.

Short Interest Ratio / Days to Cover

Virax Biolabs Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Virax Biolabs Group has recently decreased by 35.93%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.43

News Sentiment

Virax Biolabs Group has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Virax Biolabs Group this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Virax Biolabs Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.10% of the stock of Virax Biolabs Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.61% of the stock of Virax Biolabs Group is held by institutions.

VRAX Stock Analysis - Frequently Asked Questions

How have VRAX shares performed this year?

Virax Biolabs Group's stock was trading at $2.25 at the beginning of 2025. Since then, VRAX stock has decreased by 66.8% and is now trading at $0.7470.

When did Virax Biolabs Group's stock split?

Virax Biolabs Group's stock reverse split on the morning of Monday, December 18th 2023.The 1-10 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virax Biolabs Group IPO?

Virax Biolabs Group (VRAX) raised $7 million in an initial public offering (IPO) on Thursday, July 21st 2022. The company issued 1,400,000 shares at $5.00 per share. Boustead Securities served as the underwriter for the IPO.

How do I buy shares of Virax Biolabs Group?

Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Virax Biolabs Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Virax Biolabs Group investors own include Plug Power (PLUG), GeoVax Labs (GOVX), Fortress Biotech (FBIO), KALA BIO (KALA), Comtech Telecommunications (CMTL), FuelCell Energy (FCEL) and Lipocine (LPCN).

Company Calendar

• Today: 8/14/2025
• Next Earnings (Estimated): 10/01/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRAX
• CIK: 1885827
• Web: viraxbiolabs.com
• Phone: 44-0-20-7788-7414
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Virax Biolabs Group: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +293.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.27
• Quick Ratio: 7.13

Sales & Book Value

• Annual Sales: $6.33 thousand
• Price / Sales: 523.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.26 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 4,342,000
• Free Float: 2,384,000
• Market Cap: $3.31 million
• Optionable: Not Optionable
• Beta: 1.66